Endometrial Cancer

Question 1

Endometrial Carcinoma:
Primary or Adjuvant Therapy

Answer 1

Chemoradiation:
Cisplatin plus RT followed by carboplatin/paclitaxel

Systemic Therapy:
Carboplatin/paclitaxel

Carboplatin/paclitaxel/pembrolizumab (for stage III–IV tumors, except for
carcinosarcoma)

Carboplatin/paclitaxel/dostarlimab-gxly (for stage III–IV tumors)

Carboplatin/paclitaxel/trastuzumab (for stage III/IV HER2-positive)

Question 2

SYSTEMIC THERAPY FOR ENDOMETRIAL CARCINOMA:
RECURRENT DISEASE First Line

Answer 2

Preferred
Carboplatin/paclitaxel

Carboplatin/paclitaxel/pembrolizumab (except for carcinosarcoma)

Carboplatin/paclitaxel/dostarlimab-gxly (only FDA approved for dMMR/MSI-H)

Carboplatin/paclitaxel/trastuzumab
(for HER2-positive)

Other:
Carboplatin/docetaxel
Carboplatin/paclitaxel/bevacizumab

Biomarker based (only after prior platinum-based therapy):
MMR-proficient (pMMR) tumors
Lenvatinib/pembrolizumab (category 1)

TMB-H tumors
Pembrolizumab

MSI-H/dMMR tumors
Pembrolizumab
Dostarlimab-gxly